He assumed the role of Aurum Chief Science Officer in January 2014. He holds adjunct appointments as Professor at Case Western Reserve University and Rutgers-New Jersey Medical School, where he previously held full-time positions. He has published approximately 140 manuscripts*, review articles, and book chapters, mainly in the areas of tuberculosis biomarkers, immunotherapy, and anti-infective drug development. He has particular expertise in the use of innovative models to evaluate new drugs and vaccines.
Dr. Wallis came to Aurum after nearly 10 years in the pharmaceutical industry, most recently at Pfizer, where his leadership in anti-infective R&D included the TB candidate sutezolid, acquired by Sequella**. He is a member of the editorial board of the Journal of Infectious Diseases and is a Fellow of the Infectious Diseases Society of America and the Royal College of Physicians of Edinburgh. Dr. Wallis is presently leading multiple studies of adjunctive host-directed therapies in tuberculosis at Aurum.